EXS74539, also called REC-4539, is an experimental cancer drug designed to block LSD1, a protein that helps some cancer cells grow and survive even when standard treatments fail. It is being tested in a phase 1 trial on people with selected solid tumors, including small-cell lung cancer, prostate cancer, ovarian cancer and others. This early-stage […]
TSL2109 is an experimental oral cancer drug being studied in people with advanced solid tumors, especially metastatic castration-resistant prostate cancer (aka androgen pathway modulation resistant prostate cancer, or APMR, God save us!) and advanced hormone receptor–positive, HER2-negative breast cancer. It is designed to hit two important targets at once, CDK4/6 and DYRK2, which may help […]
The PRINCE trial has delivered final results showing promise for treating metastatic castration-resistant prostate cancer (mCRPC) with the combination of 177Lu-PSMA-617 (Pluvicto) and pembrolizumab. Published in The Lancet Oncology on April 1, 2026 , this single-arm, phase 1b/2 trial enrolled 37 heavily pretreated men (median age 72, 73% prior docetaxel, 100% prior AR inhibitors) who […]
Following our previous article, we are pleased to report that patient dosing has commenced in this trial. First patient has been dosed in this Phase 1 dose-escalation trial evaluating RAD 402, an anti-KLK3 (PSA) monoclonal antibody radiolabeled with Terbium-161 (Tb-161), in patients with advanced prostate cancer previously treated with standard therapies. Following our past article, […]
A promising new bispecific antibody-drug conjugate (ADC) known as IDE034 is entering early clinical testing in patients with advanced solid tumors, including prostate cancer, marking a potential step forward in precision oncology. This Phase 1a/1b trial, which began dosing its first patient in February 2026, targets tumors expressing both B7-H3 and PTK7, two surface proteins […]
Xaluritamig (AMG 509) represents a promising new immunotherapy option for men with metastatic castration-resistant prostate cancer, or mCRPC, through this new Phase 1 trial. The study aims to evaluate the safety profile of xaluritamig administered as monotherapy (plus ADT, as usual) at a specific proposed regimen in adult male participants whose cancer has progressed despite […]
MRT‑2359 is an investigational, orally bioavailable molecular‑glue degrader targeting GSPT1, a protein involved in translation termination. We talked about this new molecule in this article just one month ago, we already have some good news. In prostate cancer it is being studied in combination with androgen‑receptor (AR)‑axis inhibitors, particularly in metastatic castration‑resistant prostate cancer (mCRPC), […]
A novel approach to targeting androgen receptor signaling in prostate cancer is emerging with FX‑111, an experimental degrader that selectively removes the hormone‑bound, transcriptionally active form of the receptor known as ARon. In metastatic castration‑resistant prostate cancer (mCRPC), the androgen receptor remains a central driver in the vast majority of cases, yet resistance to current […]
A new phase 2 EQUIP trial is comparing two different ways of delivering androgen‑suppressive hormone therapy in men with newly diagnosed or recurrent metastatic hormone‑sensitive prostate cancer, focusing on whether transdermal estrogen patches can improve quality of life compared with standard luteinizing hormone‑releasing hormone (LHRH) analogues. The study is designed around two randomized cohorts, each […]
A new investigational agent code‑named GLR2037 has entered early clinical development as a first‑in‑human phase 1 study in patients with advanced prostate cancer, representing a significant step in the evolution of androgen receptor–directed therapies. GLR2037 is an androgen receptor (AR)–targeting proteolysis‑targeting chimera (PROTAC), designed not merely to inhibit the AR but to promote its ubiquitin‑proteasome–mediated […]
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlySettingsWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.
If you do not want that we track your visit to our site you can disable tracking in your browser here:
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
The following cookies are also needed - You can choose if you want to allow them:
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.
Privacy Policy